Optimization of Geminiviral Vector for Expression of Rituximab

Charles Arntzen (Inventor), Hugh Mason (Inventor)

Research output: Patent

Abstract

Production of monoclonal antibodies (mAbs) in plants has developed tremendously over the past two decades, in great part due to low production costs, scalability and lack of animal pathogen contamination. Rituximab is a chimeric monoclonal antibody against CD20 used in the treatment of lymphomas and leukemias. Rituximab has been FDA approved for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia as well as rheumatoid arthritis. Because of Rituximab's success and the expiration of its patent protection in Europe in 2013 and the US in 2018, a low cost and scalable production system would be highly advantageous. Researchers at the Biodesign Institute of Arizona State University have developed novel optimized geminiviral vectors for the expression of Rituximab in N. benthamiana. These multi-replicon single vector systems produce fully assembled Rituximab that is much more uniform in its glycan structure and at expression levels greater than 0.5 mg/g leaf. This technology, with its high yield and superior glycan structure presents a significant improvement to current Rituximab production methods. Potential Applications Plant-based production of Rituximab for research and commercial use Benefits and Advantages High-yield production capacity Uniform glycan chains on the Rituximab antibodies Can produce nonfucosylated Rituximab - research indicates that fucose in the glycan impairs function No need for non-competing viruses or co-infection with multiple expression modules Minimally sized construct Dowload Original PDF For more information about the inventor(s) and their research, please see Dr. Arntzen's directory webpage Dr. Arntzen's departmental webpage Dr. Mason's directory webpage Dr. Mason's departmental webpage
Original languageEnglish (US)
StatePublished - Jul 19 2012

Fingerprint

polysaccharides
monoclonal antibodies
non-Hodgkin lymphoma
animal pathogens
replicon
lymphocytic leukemia
rheumatoid arthritis
fucose
patents
lymphoma
leukemia
mixed infection
production costs
production technology
researchers
viruses
antibodies
leaves
methodology

Cite this

@misc{f2e92c655d23463aabf91ba4555a445e,
title = "Optimization of Geminiviral Vector for Expression of Rituximab",
abstract = "Production of monoclonal antibodies (mAbs) in plants has developed tremendously over the past two decades, in great part due to low production costs, scalability and lack of animal pathogen contamination. Rituximab is a chimeric monoclonal antibody against CD20 used in the treatment of lymphomas and leukemias. Rituximab has been FDA approved for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia as well as rheumatoid arthritis. Because of Rituximab's success and the expiration of its patent protection in Europe in 2013 and the US in 2018, a low cost and scalable production system would be highly advantageous. Researchers at the Biodesign Institute of Arizona State University have developed novel optimized geminiviral vectors for the expression of Rituximab in N. benthamiana. These multi-replicon single vector systems produce fully assembled Rituximab that is much more uniform in its glycan structure and at expression levels greater than 0.5 mg/g leaf. This technology, with its high yield and superior glycan structure presents a significant improvement to current Rituximab production methods. Potential Applications Plant-based production of Rituximab for research and commercial use Benefits and Advantages High-yield production capacity Uniform glycan chains on the Rituximab antibodies Can produce nonfucosylated Rituximab - research indicates that fucose in the glycan impairs function No need for non-competing viruses or co-infection with multiple expression modules Minimally sized construct Dowload Original PDF For more information about the inventor(s) and their research, please see Dr. Arntzen's directory webpage Dr. Arntzen's departmental webpage Dr. Mason's directory webpage Dr. Mason's departmental webpage",
author = "Charles Arntzen and Hugh Mason",
year = "2012",
month = "7",
day = "19",
language = "English (US)",
type = "Patent",

}

TY - PAT

T1 - Optimization of Geminiviral Vector for Expression of Rituximab

AU - Arntzen, Charles

AU - Mason, Hugh

PY - 2012/7/19

Y1 - 2012/7/19

N2 - Production of monoclonal antibodies (mAbs) in plants has developed tremendously over the past two decades, in great part due to low production costs, scalability and lack of animal pathogen contamination. Rituximab is a chimeric monoclonal antibody against CD20 used in the treatment of lymphomas and leukemias. Rituximab has been FDA approved for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia as well as rheumatoid arthritis. Because of Rituximab's success and the expiration of its patent protection in Europe in 2013 and the US in 2018, a low cost and scalable production system would be highly advantageous. Researchers at the Biodesign Institute of Arizona State University have developed novel optimized geminiviral vectors for the expression of Rituximab in N. benthamiana. These multi-replicon single vector systems produce fully assembled Rituximab that is much more uniform in its glycan structure and at expression levels greater than 0.5 mg/g leaf. This technology, with its high yield and superior glycan structure presents a significant improvement to current Rituximab production methods. Potential Applications Plant-based production of Rituximab for research and commercial use Benefits and Advantages High-yield production capacity Uniform glycan chains on the Rituximab antibodies Can produce nonfucosylated Rituximab - research indicates that fucose in the glycan impairs function No need for non-competing viruses or co-infection with multiple expression modules Minimally sized construct Dowload Original PDF For more information about the inventor(s) and their research, please see Dr. Arntzen's directory webpage Dr. Arntzen's departmental webpage Dr. Mason's directory webpage Dr. Mason's departmental webpage

AB - Production of monoclonal antibodies (mAbs) in plants has developed tremendously over the past two decades, in great part due to low production costs, scalability and lack of animal pathogen contamination. Rituximab is a chimeric monoclonal antibody against CD20 used in the treatment of lymphomas and leukemias. Rituximab has been FDA approved for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia as well as rheumatoid arthritis. Because of Rituximab's success and the expiration of its patent protection in Europe in 2013 and the US in 2018, a low cost and scalable production system would be highly advantageous. Researchers at the Biodesign Institute of Arizona State University have developed novel optimized geminiviral vectors for the expression of Rituximab in N. benthamiana. These multi-replicon single vector systems produce fully assembled Rituximab that is much more uniform in its glycan structure and at expression levels greater than 0.5 mg/g leaf. This technology, with its high yield and superior glycan structure presents a significant improvement to current Rituximab production methods. Potential Applications Plant-based production of Rituximab for research and commercial use Benefits and Advantages High-yield production capacity Uniform glycan chains on the Rituximab antibodies Can produce nonfucosylated Rituximab - research indicates that fucose in the glycan impairs function No need for non-competing viruses or co-infection with multiple expression modules Minimally sized construct Dowload Original PDF For more information about the inventor(s) and their research, please see Dr. Arntzen's directory webpage Dr. Arntzen's departmental webpage Dr. Mason's directory webpage Dr. Mason's departmental webpage

M3 - Patent

ER -